Endocrine Abstracts

Introduction: Maturity-onset diabetes of the young (MODY) represents 1 to 2% of all cases of diabetes. MODY-3 is the most prevalent subtype and is characterized by a high sensitivity to sulfonylurea (SU) therapy. To date, we have scarce evidence about the efficacy of other therapies in this population, namely GLP-1 receptor agonists (GLP-1ra). Objective: Evaluate the metabolic impact of GLP-1ra use in MODY-3 patients.Methods: Retro...